| Autor: |
Min Xu, Jinhui Shu, Shenxian Qian, Jingming Guo, Yuping Gong, Ruibin Huang, Shuye Wang, Zeping Zhou, Guolin Yuan, Meijuan Huang, Li-E Lin, Shifeng Lou, Yanping Song, Qingchi Liu, Hu Zhou, Heng Mei, Yu Hu |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
The Lancet Regional Health. Western Pacific, Vol 47, Iss , Pp 101096- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2666-6065 |
| DOI: |
10.1016/j.lanwpc.2024.101096 |
| Popis: |
Summary: Background: Primary immune thrombocytopenia (ITP) is an autoimmune disease, and rituximab (RTX) induces long-term effect as second-line treatments. Zuberitamab is an innovative anti-CD20 monoclonal antibody, which was first developed in China and launched in diffuse large B lymphoma. This study aimed to investigate the safety, efficacy, and anticipated therapeutic dose of zuberitamab in Chinese ITP patients. Methods: This randomised, double-blind, placebo-controlled, phase 2 study was conducted at 26 hospitals in China. Eligible patients were aged 18–70 years, had primary immune thrombocytopenia for more than 6 months, and did not respond or relapsed after previous treatment and had a pre-treatment platelet count of |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
